利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.014 秒)

    COMBINATION THERAPIES FOR TREATING METABOLIC DISORDERS
    1.
    发明公开
    COMBINATION THERAPIES FOR TREATING METABOLIC DISORDERS 审中-公开
    联合治疗代谢疾病的治疗

    公开(公告)号：EP2408441A1

    公开(公告)日：2012-01-25

    申请号：EP10710278.2

    申请日：2010-03-16

    申请人： Genmedica Therapeutics SL

    发明人： MAYOUX, Eric ,  MARTI CLAUZEL, Luc ,  GARCIA VICENTE, Silvia ,  SERRANO MUÑOZ, Marta ,  ZORZANO OLARTE, Antonio ,  MIAN, Alec

    IPC分类号： A61K31/00 ,  A61K31/192 ,  A61K31/196 ,  A61K31/198 ,  A61K31/385 ,  A61K31/60 ,  A61P3/06 ,  A61P3/08

    CPC分类号： A61K31/198 ,  A61K31/00 ,  A61K31/192 ,  A61K31/196 ,  A61K31/385 ,  A61K31/60 ,  A61K45/06 ,  A61K2300/00

    摘要： This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable earner. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and/or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient.